Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. James Q. Del Rosso on Innovative Therapies
James Del Rosso, DO, FAOCD
Joel L. Cohen, MD, FAAD, FACMS
Pediatric Roundup: Pearls from SDPA Summer Conference 2024
Lisa Swanson, MD, FAAD
Turmeric Tonic as a Treatment in Scalp Psoriasis
Peter A. Lio, MD
Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
Christopher Bunick, MD, PhD
Loading...
Stay current with the best on medical education
We’re glad to see you’re enjoying PracticalDermatology… but how about a more personalized experience?
Press cancel to remain on PracticalDermatology. Press the link below or the continue button to keep going.